Jan Nilsson will attend Swiss Nordic Bio, partnering and investor conference
On February 6, CombiGene’s CEO Jan Nilsson will attend Swiss Nordic Bio, partnering and investor conference aimed at connecting investor and industry. In the morning, Jan will present CombiGene to some one hundred investors, while the afternoon is dedicated for one on one meetings.
The conference is organized by the Nordic countries in cooperation with Swiss partners.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.